CollPlant Biotechnologies Ltd Ordinary Shares New CLGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLGN is a good fit for your portfolio.
News
-
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
-
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
-
CollPlant Issues Letter to Shareholders
Trading Information
- Previous Close Price
- $6.24
- Day Range
- $5.90–6.75
- 52-Week Range
- $4.22–8.90
- Bid/Ask
- $4.01 / $10.77
- Market Cap
- $77.32 Mil
- Volume/Avg
- 13,256 / 6,664
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 73
- Website
- https://www.collplant.com
Comparables
Valuation
|
Metric
|
CLGN
|
02172
|
ARX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 24.82 | — |
Price/Book Value | 2.52 | 3.06 | 1.93 |
Price/Sales | 6.48 | 7.50 | 2.89 |
Price/Cash Flow | — | 21.79 | — |
Price/Earnings
CLGN
02172
ARX
Financial Strength
|
Metric
|
CLGN
|
02172
|
ARX
|
|---|---|---|---|
Quick Ratio | 8.33 | 4.17 | 5.57 |
Current Ratio | 8.62 | 5.35 | 7.83 |
Interest Coverage | — | 43.05 | — |
Quick Ratio
CLGN
02172
ARX
Profitability
|
Metric
|
CLGN
|
02172
|
ARX
|
|---|---|---|---|
Return on Assets (Normalized) | −13.90% | 8.50% | — |
Return on Equity (Normalized) | −16.34% | 10.32% | — |
Return on Invested Capital (Normalized) | −17.09% | 9.14% | — |
Return on Assets
CLGN
02172
ARX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sbzdrjlz | Bgl | $567.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cpcrydjy | Cjfjc | $108.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xltcxrlb | Yspwfn | $105.3 Bil | |
MRNA
| Moderna Inc | Krvjptrd | Rnltp | $47.0 Bil | |
ARGX
| argenx SE ADR | Dlgsnsbxg | Gvqm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dhwntvgk | Mmxzr | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nhhclpkwk | Nyvpkjz | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xzdpxbnwv | Yzkwzt | $15.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fczcgrlnh | Zxmrrpc | $12.6 Bil | |
INCY
| Incyte Corp | Vjnyntg | Ttrrrp | $12.0 Bil |